Search bioRxiv⌕ Search

Biology subjects

Grodeland, G.

Publications and source records attributed to Grodeland, G..

4 recordsLinked to original sources

Influenza H1N1 Imprinting Uncouples Serological and B-Cell Responses in Mice

Antigenic drift reduces the protective potential of antibodies generated against earlier influenza variants. Unfortunately, a new infection or vaccination often preferentially recalls antibodies targeting previously encountered strains, thereby limiting responses to newly emerged variants. Although this phenomenon, known as immunological imprinting, has been well documented at the serological level, its underlying cellular mechanisms remain poorly understood. To resolve imprinting at both the serological and cellular level, we combined serum antibody profiling with targeted B-cell characterization in mice, including single-cell B-cell receptor (BCR) sequencing of germinal center (GC) B cells following secondary H1N1 challenge and bulk BCR sequencing of bone marrow plasma cells. We found that a primary infection with the 2009 pandemic H1N1 ("swine flu") strain largely prevented the generation of new serum antibodies following secondary exposure to the antigenically distinct H1N1 strain A/Puerto Rico/8/1934 (PR8), whereas the reciprocal infection sequence updated antibody specificities towards the last encountered virus. GC B cells did not mirror serological imprinting and instead generated updated BCR repertoires directed against the heterologous challenge strain. Likewise, BCR diversity in draining lymph node B cells failed to mirror the serological imprinting observed in the antibody response. Together, these findings reveal a striking uncoupling of cellular and serological immune responses during influenza imprinting, highlighting the need to study both compartments to better understand immune memory and guide the development of improved seasonal influenza vaccines across a diverse population.

immunology↗

Multiplexed measurement of binding- and neutralizing antibodies to SARS-CoV-2 variants in 12.000 post-vaccine sera

Diagnostic assays currently used to monitor the efficacy of COVID-19 vaccines measure levels of antibodies to the receptor-binding domain of ancestral SARS-CoV-2 (RBDwt). However, the predictive value for protection against new variants of concern (VOCs) has not been firmly established. Here, we used bead-based arrays and flow cytometry to measure binding of antibodies to spike proteins and receptor-binding domains (RBDs) from VOCs in 12,000 sera. Effects of sera on RBD-ACE2 interactions were measured as a proxy for neutralizing antibodies. The samples were obtained from healthy individuals or patients on immunosuppressive therapy who had received two to four doses of COVID-19 vaccines and from COVID-19 convalescents. The results show that anti-RBDwt titers correlate with the levels of binding- and neutralizing antibodies against the Alpha, Beta, Gamma, Delta, Epsilon and Omicron variants. The benefit of multiplexed analysis lies in the ability to measure a wide range of anti-RBD titers using a single dilution of serum for each assay. The reactivity patterns also yield an internal reference for neutralizing activity and binding antibody units per milliliter (BAU/ml). Results obtained with sera from vaccinated healthy individuals and patients confirmed and extended results from previous studies on time-dependent waning of antibody levels and effects of immunosuppressive agents. We conclude that anti-RBDwt titers correlate with levels of neutralizing antibodies against VOCs and propose that our method may be implemented to enhance the precision and throughput of immunomonitoring.

immunology↗

Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection in vitro and in vivo

SARS-CoV-2 and its vaccine/immune-escaping variants continue to pose a serious threat to public health due to a paucity of effective, rapidly deployable, and widely available treatments. Here, we address these challenges by combining Pegasys (IFNa) and nafamostat to effectively suppress SARS-CoV-2 infection in cell culture and hamsters. Our results indicate that Serpin E1 is an important mediator of the antiviral activity of IFNa and that both Serpin E1 and camostat can target the same cellular factor TMPRSS2, which plays a critical role in viral replication. The low doses of the drugs in combination may have several clinical advantages, including fewer adverse events and improved patient outcome. Thus, our study may provide a proactive solution for the ongoing pandemic and potential future coronavirus outbreaks, which is still urgently required in many parts of the world.

microbiology↗

Synergistic interferon alpha-based drug combinations inhibit SARS-CoV-2 and other viral infections in vitro

There is an urgent need for new antivirals with powerful therapeutic potential and tolerable side effects. In the present study, we found that recombinant human interferon-alpha (IFNa) triggers intrinsic and extrinsic cellular antiviral responses, as well as reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro. Although IFNa alone was insufficient to completely abolish SARS-CoV-2 replication, combinations of IFNa with remdesivir or other antiviral agents (EIDD-2801, camostat, cycloheximide, or convalescent serum) showed strong synergy and effectively inhibited SARS-CoV-2 infection in human lung epithelial Calu-3 cells. Furthermore, we showed that the IFNa-remdesivir combination suppressed virus replication in human lung organoids, and that its single prophylactic dose attenuated SARS-CoV-2 infection in lungs of Syrian hamsters. Transcriptome and metabolomic analyses showed that the combination of IFNa-remdesivir suppressed virus-mediated changes in infected cells, although it affected the homeostasis of uninfected cells. We also demonstrated synergistic antiviral activity of IFNa2a-based combinations against other virus infections in vitro. Altogether, our results indicate that IFNa2a-based combination therapies can achieve higher efficacy while requiring lower dosage compared to monotherapies, making them attractive targets for further pre-clinical and clinical development.

microbiology↗